The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | All-CLL: an NGS panel for molecular characterization of CLL
In this interview, Ferran Nadeu, PhD, IDIBAPS, Barcelona, Spain, introduces All-CLL, a capture-based next-generation sequencing (NGS) panel developed to facilitate routine molecular characterization of chronic lymphocytic leukemia (CLL) which may aid in identification of the immunogenetic and genomic drivers of the disease. All-CLL involves a single assay which integrates characterization of the driver gene mutations, the main chromosomal alterations, and mutations in the immunoglobulin gene. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
